Metabolic Restoration through Nutritional Detoxification in Non-Alcoholic Fatty Liver: A Mini-Review
About a third of the global population suffers from non-alcoholic fatty liver disease (NAFLD). The disease develops with no specific signs along with other co-morbidities. Both genetic polymorphisms and external risk factors are correlated with the disease. NAFLD is characterized by the accumulation of fat within hepatocytes that precede its progression to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma/hepatic failure. The standard management involves compliance with a fat and sugar-poor diet as well as other lifestyle alterations. Nonetheless, recent studies have shown that some foods and nutraceuticals exhibited beneficial effects toward NAFLD. This paper offers a short review of the pathophysiology, risk factors, and nutritional detoxification of NAFLD.
1. Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S32–42.
2. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken) 2021;17:365–70.
3. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7:851–61.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver diseaseMeta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
5. Henry L, Paik J, Younossi ZM. Review article: The epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022;56:942–56.
6. Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J Hepatol 2016;8:827–37.
7. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis. Am J Gastroenterol 2014;109:325–34.
8. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015;35:270–90.
9. Khatib MN, Gaidhane S, Gaidhane AM, Simkhada P, Zahiruddin QS. Ghrelin O Acyl Transferase (GOAT) as a novel metabolic regulatory enzyme. J Clin Diagn Res 2015;9:LE01–5.
10. Abdel-Rahman RF. Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. Asian Pac Trop Biomed 2022;12:99–114.
11. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011;140:124–31.
12. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study. J Gastroenterol 2012;47:586–95.
13. Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol 2023;79:287–95.
14. Alalwani J, Eljazzar S, Basil M, Tayyem R. The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review. Clin Obes 2022;12:e12525.
15. Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A, et al. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 diabetes, and non-viral hepatocarcinoma: Pathophysiological mechanisms and new therapeutic strategies. Biomedicines 2023;11:468.
16. Lorbeer R, Bayerl C, Auweter S, Rospleszcz S, Lieb W, Meisinger C, et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens 2017;35:737–44.
17. Pezzino S, Sofia M, Faletra G, Mazzone C, Litrico G, La Greca G, et al. Gut-liver axis and non-alcoholic fatty liver disease: A vicious circle of dysfunctions orchestrated by the gut microbiome. Biology (Basel) 2022;11:1622.
18. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annu Rev Pathol 2016;11:451–96.
19. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 2019;103:e1–13.
20. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–51.
21. Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770.
22. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753–61.
23. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908–22.
24. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 2018;68:280–95.
25. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, AraujoPerez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764–75.
26. Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis. J Lipid Res 2016;57:1758–70.
27. Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497–507.
28. Rabinowich L, Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. Biomed Res Int 2015;2015:168905.
29. Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res (Camb) 2018;7:664–80.
30. Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-induced aggravation of metabolic-associated fatty liver disease. Int J Mol Sci 2022;23:1062.
31. Gu X, Manautou JE. Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med 2012;14:e4.
32. Mackowiak B, Hodge J, Stern S, Wang H. The roles of xenobiotic receptors: Beyond chemical disposition. Drug Metab Dispos 2018;46:1361–71.
33. Berná G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int 2020;40:102–8.
34. De Chiara F, Ureta Checcllo C, Ramón Azcón J. High protein diet and metabolic plasticity in non-alcoholic fatty liver disease: Myths and truths. Nutrients 2019;11:2985.
35. Mehedint MG, Zeisel SH. Choline’s role in maintaining liver function: New evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care 2013;16:339–45.
36. El-Din SHS, Sabra A-NA, Hammam OA, Ebeid FA, El-Lakkany NM. Pharmacological and antioxidant actions of garlic and. or onion in non-alcoholic fatty liver disease (NAFLD) in rats. J Egypt Soc Parasitol 2014;44:295–308.
37. Soleimani D, Paknahad Z, Rouhani MH. Therapeutic effects of garlic on hepatic steatosis in nonalcoholic fatty liver disease patients: A randomized clinical trial. Diabetes Metab Syndr Obes 2020;13:2389–97.
38. Yu L, Zhao R, Wang C, Zhang C, Chu C, Zhao J, et al. Effects of garlic supplementation on non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. J Func Foods 2022;99:105294.
39. Martini R, Butler AM, Jiang XM, Murray M. Pretranslational down regulation of cytochrome P450 2C11 in vitamin A-deficient male rat liver: Prevention by dietary inclusion of retinoic acid. J Pharmacol Exp Ther 1995;273:427–34.
40. Vadarlis A, Antza C, Bakaloudi DR, Doundoulakis I, Kalopitas G, Samara M, et al. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:311–9.
41. Santacroce G, Gentile A, Soriano S, Novelli A, Lenti MV, Di Sabatino A. Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. Front Med (Lausanne) 2023;10:1124275.
42. Minich DM, Brown BI. A review of dietary (phyto)nutrients for glutathione support. Nutrients 2019;11:2073.
43. Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arc Biochem Biophys 2004;423:6–11.
44. Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One 2016;11:e0151829.
45. Gottlieb A, Canbay A. Why Bile acids are so important in Non-Alcoholic Fatty Liver Disease (NAFLD) progression. Cells 2019;8:1358.
46. Huang W, Wang G, Xia Y, Xiong Z, Ai L. Bile salt hydrolaseoverexpressing lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food Nutr Res 2020;64.
47. De Nucci S, Rinaldi R, Di Chito M, Donghia R, Giannuzzi V, Shahini E, et al. The replacement of only one portion of starchy carbohydrates with green leafy vegetables regresses mid and advanced stages of NAFLD: Results from a prospective pilot study. Nutrients 2023;15:2289.
48. Lundberg JO, Carlström M, Weitzberg E. Metabolic effects of dietary nitrate in health and disease. Cell Metab 2018;28:9–22.
49. Mokhtari E, Farhadnejad H, Salehi-Sahlabadi A, Najibi N, Azadi M, Teymoori F, et al. Spinach consumption and nonalcoholic fatty liver disease among adults: A case–control study. BMC Gastroenterol 2021;21:196.
50. Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 2020;158:1597–610.
51. Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: A meta-analysis. Dig Dis Sci 2019;64:3402–12.
52. Almeida JI, Tenreiro MF, Martinez-Santamaria L, GuerreroAspizua S, Gisbert JP, Alves PM, et al. Hallmarks of the human intestinal microbiome on liver maturation and function. J Hepatol 2022;76:694–725.
53. Średnicka P, Juszczuk-Kubiak E, Wójcicki M, Akimowicz M, Roszko MŁ. Probiotics as a biological detoxification tool of food chemical contamination: A review. Food Chem Toxicol 2021;153:112306.